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Today, heart transplantation is the golden standard for the
treatment of patients with end-stage heart failure. A median
survival time of more than 11 years (and 13 years for those
surviving the first year) after transplantation will be hard to
equal let alone to beat [1]. As a result of donor organ shortage,
transplantation can, unfortunately, only be offered to a
few patients. Supported by considerable improvements
in left ventricular assist devices (LVADs) cardiologists
and surgeons in the USA, as well as elsewhere in Europe,
are eagerly accepting the LVAD as a long-term therapy
(destination therapy).
Historically, LVADs were used as a bridge to a transplan-
tation (BTT) or bridge to recovery in the very few patients
whose heart function improved after a period of mechanical
support. In less than two decades LVADs have evolved from
short-term axial extracorporeal pulsatile devices to smaller
intracorporeal continuous flow devices for long-term support.
In doing so, the complication rates have dropped considerably
and an additional treatment for end-stage heart failure has
become a reality, paving the way for LVAD as long-term
therapy. Patients who are deemed unfit for transplantation
can now be offered an alternative therapy. It is important,
however, to realise that the indications of BTTand destination
therapy will no longer be mutually exclusive; they may be a
moving target. For example, patients on destination
therapy may become BTT patients over time due to
the fact that a contraindication for transplantation has
disappeared: e.g. they have survived their malignancy
long enough or their pulmonary pressures have normalised.
On the other hand, patients on BTT therapy might become
destination therapy patients if they develop a malignancy
during the waiting time.
The two leading LVAD devices currently on the market are
the Heart Mate II and HeartWare. In the United States the
Heart Mate II has been approved for BTT since 2008 and as
destination therapy since 2010, while HeartWare is approved
as BTT since 2010 and is still awaiting approval for destina-
tion therapy. During 2012 more than 40 % of all implants in
the USA were designated as destination therapy [2]. In
Europe, the current Heart Mate II ratio BTT/ destination
therapy is 75 %/25 % (information from Thoratec Corp).
In the Netherlands, mechanical support by an LVAD is only
reimbursed by the Health Insurance Companies when used as
a BTT. In a recent consensus document, the Netherlands
Society of Cardiology and the Netherlands Society of
Thoracic Surgery express the opinion that LVAD destination
therapy should be part of our therapeutic armamentarium
(August 2014). For this purpose they formulated indications
and contraindications for destination therapy as well as spe-
cific requirements for the implanting teams.
In this issue of the Netherlands Heart Journal, Haeck et al.
from Leiden University Medical Centre report their experi-
ence in the use of LVADs as destination therapy [3]. They
have to be congratulated on being the front runners on this
subject in the Netherlands. Without experience in the applica-
tion of LVADs as BTT they selected 16 patients with end-
stage heart failure who remained symptomatic (NYHA class
III or more), were on optimal medical therapy and were
considered ineligible for transplantation. In these patients,
who are at high risk of dying in the short term, they show
improvements in NYHA class, in quality of life as well as
in 6-min walking distance.
In the Discussion section, Haeck et al. argue that treatment
with LVADs results in nearly the same outcome as with heart
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transplantation (1- and 2-year survival of 80 % and 70 %
respectively) [2]. It is suggested that their 6-month survival
is in line with the expectations. These statements, however,
need nuance. Data about long-term destination therapy with
an LVAD are totally absent; therefore a real comparison with
heart transplantation cannot be made. In addition, Haeck et al.
do not present data about the length of follow-up. In view of
the start of their program in November 2010 (Leids Dagblad,
16 November 2010) one could expect that the 1- and 2-year
survival rates could have been presented. Of course, such data
would have to be interpreted with great caution for two
reasons. The number of patients in their study was very small
and the team had no experience in the application of LVADs as
BTT. The latter must be kept in mind when comparing their
results with the published USA data of centres with experi-
ence of the implantation of LVADs as BTT. The sixth
Interagency Registry for Mechanically Assisted Circulatory
Support (INTERMACS) annual report shows that the survival
rates of more than 10,000 patients are 80 %, 70 %, 59 % and
47 % after 1, 2, 3 and 4 years, respectively.[2] The 6-month
survival of Haeck et al. is already less than the 1-year survival
in the INTERMACS registry. Apart from the lack of experi-
ence there are various reasons why this may be so. First of all,
they included two patients in INTERMACS level 1, who are
at the highest risk of dying. Furthermore, they also included a
high percentage of patients (81 %) who had to undergo
concomitant tricuspid valve annuloplasty. It has been shown
that performing a tricuspid valve procedure for severe tricus-
pid valve regurgitation does not reduce early death or right-
sided VAD requirement and that this is associated with worse
early postoperative outcomes [4]. Finally, it is known that
patients on destination therapy are at higher risk of death than
patients on BTT [2].
The rates of adverse clinical events in the studied group
(44 %) are somewhat lower than those in the INTERMACS
registry (60 % at 6 months) [2]. But the numbers are low and
the presented data do not include the in-hospital events. In
general, with such a high percentage of adverse clinical events
it is not a question of whether patients will have a complica-
tion, but rather when. The hope is that in the future, with the
use of newer-generation LVADs, these event rates will go
down. This is of special importance for patients on destination
therapy since they have limited bail out options when
problems occur.
Looking into the future, I think that we have to rely on
international data to decide upon the approval of LVAD des-
tination therapy as reimbursed care. Results from centres
abroad combined with the experience in BTT of the Dutch
heart transplant centres make a randomised trial (medical
therapy versus destination therapy) unacceptable. LVAD as
destination therapy is around the corner but improvement in
patient selection, miniaturising of the LVAD, complete
internalisation of the power source and placement with min-
imally invasive surgical techniques are necessary to make this
a successful transition. Furthermore, the price per LVAD
needs to come down as more are being implanted. As col-
leagues in Utrecht have recently shown, LVAD destination
therapy is still a relatively expensive intervention (€107,600
per quality-adjusted life-years) [5]. Thus costingmore than the
€80,000 which was suggested as an upper limit by the
Netherlands Council for Health and Care in 2006 [6].
An exciting new time is ahead, and we need to keep in
mind that as the number of LVAD patients grows we will
reach a point that also not-implanting, referring hospitals will
have to take over part of the care of LVAD patients as well. A
real challenge for all Dutch cardiologists.
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